SCHEMBL804888

SCHEMBL804888

COc1nc2c(ccc3ccccc32)nc1C(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.40
PRMT3 O60678 1/20 0.40
CARM1 Q86X55 1/20 0.40
EHMT2 Q96KQ7 1/20 0.40
PRMT6 Q96LA8 1/20 0.40
PRMT1 Q99873 1/20 0.40
WDR77 Q9BQA1 1/20 0.40
SLC2A1 P11166 1/20 0.40
CYP1A2 P05177 3/20 0.39
CYP2C19 P33261 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPT P10636 3/20 0.39
MAOA P21397 1/20 0.37
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL789338 0.86 MAPT (0.43) PRMT5PRMT3CARM1EHMT2PRMT6
SCHEMBL22369924 0.85 GAA (0.40) PRMT5PRMT3CARM1EHMT2PRMT6
SCHEMBL15423524 0.83 PRMT5 (0.46) PRMT5PRMT3CARM1EHMT2PRMT6
SCHEMBL789344 0.82 MAPT (0.42) PRMT5PRMT3CARM1EHMT2PRMT6
SCHEMBL10111419 0.81 PRMT5 (0.45) PRMT5PRMT3CARM1EHMT2PRMT6
SCHEMBL22369921 0.81 GAA (0.43) PRMT5PRMT3CARM1EHMT2PRMT6
SCHEMBL8024194 0.78 NQO2 (0.44) CYP1A2CYP2C19ALDH1A1MAPTPOLB
SCHEMBL805028 0.78 PRMT5 (0.42) PRMT5PRMT3CARM1EHMT2PRMT6
SCHEMBL24702682 0.75 LMNA (0.41) PRMT5PRMT3CARM1EHMT2PRMT6
SCHEMBL25821952 0.75 PRMT5 (0.40) PRMT5PRMT3CARM1EHMT2PRMT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070416-A1 Macrocyclic Proline Derived HCV Serine Protease Inhibitors ENANTA PHARMACEUTICALS, INC. 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120070416-A1 Macrocyclic Proline Derived HCV Serine Protease Inhibitors PREP, PRSS1, PEPD PRMT5 1655/4885PRMT3 1159/4885CARM1 4488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.